Invitae (NYSE:NVTA) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Invitae (NYSE:NVTA) in a research note released on Thursday morning. The firm issued a hold rating on the medical research company’s stock.

Invitae Price Performance

NYSE:NVTA opened at $0.00 on Thursday. Invitae has a 52-week low of $0.02 and a 52-week high of $0.02. The stock has a market cap of $80,103.00, a P/E ratio of 0.00 and a beta of 1.59.

Institutional Trading of Invitae

An institutional investor recently bought a new position in Invitae stock. Vestmark Advisory Solutions Inc. purchased a new stake in Invitae Co. (NYSE:NVTA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 839,007 shares of the medical research company’s stock, valued at approximately $526,000. Vestmark Advisory Solutions Inc. owned about 0.29% of Invitae at the end of the most recent quarter. 61.28% of the stock is currently owned by institutional investors and hedge funds.

Invitae Company Profile

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.